当前位置:首页 - 行情中心 - 易明医药(002826) - 财务分析 - 利润表

易明医药

(002826)

  

流通市值:26.92亿  总市值:27.88亿
流通股本:1.84亿   总股本:1.91亿

利润表

报告期2026-09-302026-06-302026-03-312025-12-31
公司类型通用通用通用通用
一、营业总收入562,069,352.56359,623,665.2182,577,229.06636,272,038.57
  营业收入562,069,352.56359,623,665.2182,577,229.06636,272,038.57
二、营业总成本466,546,362.35305,912,646.03157,841,477.13573,356,762.17
  营业成本100,885,609.5364,644,657.5231,988,009.5113,814,862.53
  税金及附加9,821,406.996,425,839.263,246,173.8611,577,212.77
  销售费用276,134,629.35191,440,486.6198,853,901.48346,645,165.12
  管理费用76,833,51642,389,577.9223,553,149.3386,933,099.17
  研发费用3,823,361.751,782,105.9599,923.3914,670,208.35
  财务费用-952,161.27-770,021.18-399,680.43-283,785.77
  其中:利息费用454,914.62116,866.2927,519.621,000,392.18
  其中:利息收入748,700.93452,650.77198,988.17444,924.84
三、其他经营收益
  加:投资收益2,805,250.851,743,179.51203,279.573,496,674.69
  资产处置收益-87,487.98-87,487.98-87,487.98-231,318.41
  资产减值损失(新)-397,493.01---2,727,108.33
  信用减值损失(新)-1,442,630.49-435,423.75-431,008.171,195,607.72
  其他收益28,297,643.2528,126,260.7459,989.7535,963,791.12
四、营业利润124,698,272.8383,057,547.6524,880,525.1100,612,923.19
  加:营业外收入158,374.24103,233.7234,504.2215,168,743.49
  减:营业外支出1,440,461.86143,642.286,522.482,111,159.25
五、利润总额123,416,185.2183,017,139.0924,908,506.84113,670,507.43
  减:所得税费用24,057,216.7816,337,444.535,260,136.4320,546,373.98
六、净利润99,358,968.4366,679,694.5619,648,370.4193,124,133.45
(一)按经营持续性分类
  持续经营净利润99,358,968.4366,679,694.5619,648,370.4193,124,133.45
(二)按所有权归属分类
  归属于母公司股东的净利润99,358,968.4366,679,694.5619,648,370.4192,580,749
  少数股东损益---543,384.45
  扣除非经常损益后的净利润74,336,627.2941,642,774.7819,276,554.5148,989,988.94
七、每股收益
  (一)基本每股收益0.540.360.110.5
  (二)稀释每股收益0.540.360.110.5
八、其他综合收益-1,121,308.17-938,922.36-653,642.24-1,071,743.36
  归属于母公司股东的其他综合收益-1,121,308.17-938,922.36-653,642.24-1,071,743.36
九、综合收益总额98,237,660.2665,740,772.218,994,728.1792,052,390.09
  归属于母公司股东的综合收益总额98,237,660.2665,740,772.218,994,728.1791,509,005.64
  归属于少数股东的综合收益总额---543,384.45
公告日期2026-10-282026-08-272026-04-282026-04-28
审计意见(境内)标准无保留意见
TOP↑